Research compares differences in brain biomarkers between younger and older participants without cognitive impairment to participants who have Alzheimer’s. 
Keck School of Medicine logo

More Details About the Study

This research is intended to learn more about how plasma exosome biomarkers are expressed in the brains of individuals with cognitive impairment (like Alzheimer’s Disease) to better diagnose, monitor, and treat cognitive impairment. The results of this study may be used to provide further evidence for the efficacy of phenserine for future clinical trials.

What is the duration of the study? How long will I participate for?

This study will be 12-weeks long and includes 3 in-person clinic visits at screening, baseline, and week 12 follow up visit. This study will include memory testing and a blood draw for blood sample collection. You will be compensated for completing the baseline and 12-week follow-up visits.

Share this study


More studies


The next phase of Alzheimer’s Disease Neuroimaging Initiative (ADNI) research, ADNI4 is now recruiting participants with or without memory issues to help us continue investigating important questions concerning early detection of mild cognitive impairment and Alzheimer’s Disease.

Read more »
Skip to content